A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2006
05/18/2006	WO2006051408A1 Oxazolidinone derivatives as antimicrobials
05/18/2006	WO2006051407A1 Azabenzoxazoles for the treatment of cns disorders
05/18/2006	WO2006051399A1 Piperazine derivatives useful as adrenergic receptor antagonists
05/18/2006	WO2006051394A1 Azabenzoxazoles for the treatment of cns disorders
05/18/2006	WO2006051390A1 Heterocyclic compounds useful for the treatment of inflammatory and allergic disorders, pharmaceutical compositions containing them, and methods of preparing them
05/18/2006	WO2006051378A1 Substituted n-sulfonylaminobenzyl-2-phenoxy acetamide compounds
05/18/2006	WO2006051375A1 L-tartrate salt of n-1-adamanthyl -2-{3-[(2r)-2- ({(2r)-2-hydroxy -2- [4-hydroxy-3- (hydroxymethyl) phenyl]ethyl} amino)propyl] phenyl} acet amide
05/18/2006	WO2006051374A2 Arylpiperazines useful as adrenergic receptor antagonists
05/18/2006	WO2006051373A1 Compounds for the treatment of diseases
05/18/2006	WO2006051341A1 Isotopically marked quinoline derivatives as adenosin a3 receptor ligands
05/18/2006	WO2006051340A1 Novel form of celecoxib
05/18/2006	WO2006051334A1 Plant cells and uses thereof
05/18/2006	WO2006051314A2 Guanidine derivatives as inhibitors of ddah
05/18/2006	WO2006051312A1 Gastrin and cholecystokinin receptor ligands
05/18/2006	WO2006051311A1 Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
05/18/2006	WO2006051290A2 Compounds for treating protein-kinase mediated disorders
05/18/2006	WO2006051270A1 5-heteroaryl thiazoles and their use as p13k inhibitors
05/18/2006	WO2006051269A1 Treatment of acne using derivatives of 5-aminolevulinic acid
05/18/2006	WO2006051202A1 Derivatives of 4,7-dioxobenzothiazole-2-carboxamides, preparation method thereof and therapeutic uses of same
05/18/2006	WO2006051154A1 Treatment of restless legs syndrome
05/18/2006	WO2006051137A1 Method of obtaining derivatives of 4-(n-alkylamine)-5,6-dihydro-4h-thieno-[2,3-b]-thiopyran
05/18/2006	WO2006051111A1 S-mirtazapine for the treatment of hot flush
05/18/2006	WO2006051106A1 Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
05/18/2006	WO2006051067A1 A process for preparing formulations of lipophilic active substances by spray freeze drying
05/18/2006	WO2006050998A1 5-substituted quinoline and isoquinoline derivatives, a method for the production thereof and their use as antiphlogistics
05/18/2006	WO2006050992A1 Compounds having activity at nk3 receptor and uses thereof in medicine
05/18/2006	WO2006050991A1 Compounds having activity at nk3 receptor and uses thereof in medicine
05/18/2006	WO2006050989A1 Compounds having activity at nk3 receptor and uses thereof in medicine
05/18/2006	WO2006050976A1 Azaindole carboxamides
05/18/2006	WO2006050975A1 Nutrition containing fat blend
05/18/2006	WO2006050965A1 Pyrimidine compounds as histamine modulators
05/18/2006	WO2006050951A1 Novel composition for easing human child birth
05/18/2006	WO2006050949A2 Superagonistic anti-cd28 antibody
05/18/2006	WO2006050946A1 1,4 substituted pyrazolopyrimidines as kinase inhibitors
05/18/2006	WO2006050943A1 Macrolone compounds
05/18/2006	WO2006050942A1 Macrolones - amino substituted quinolones
05/18/2006	WO2006050941A1 Macrolone compounds
05/18/2006	WO2006050940A1 Macrolone compounds
05/18/2006	WO2006050926A2 Extended surface aggregates in the treatment of skin conditions
05/18/2006	WO2006050923A1 Polymorph form of irbesartan
05/18/2006	WO2006050921A2 Preparation of telmisartan salts with improved solubility
05/18/2006	WO2006050909A1 Novel forms of efletirizine dihydrochloride, processes for making them and pharmaceutical compositions including them
05/18/2006	WO2006050908A1 Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1)
05/18/2006	WO2006050843A1 Aminoquinazolines compounds
05/18/2006	WO2006050842A1 Dibenzosuberone derivatives
05/18/2006	WO2006050830A1 Substituted benzoylguanidines method for production and use thereof as medicament or diagnostic and medicament comprising the same
05/18/2006	WO2006050826A2 Treatment of mastitis with enrofloxacin
05/18/2006	WO2006050816A1 Anti-demodicosis agent
05/18/2006	WO2006050800A1 4-amino-5-oxo-8-phenyl-5h-pyrido-[2,3-d]-pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours
05/18/2006	WO2006050794A1 Use of acetyl l-carnitine in combination with propionyl l-carnitine and sildenafil for the treatment of erectile dysfunction
05/18/2006	WO2006050779A1 N,n'-diphenyl urea derivatives suitable as kinase inhibitors
05/18/2006	WO2006050734A2 Potent lna oligonucleotides for the inhibition of hif-1a expression
05/18/2006	WO2006050732A2 Lna oligonucleotides and the treatment of cancer
05/18/2006	WO2006050730A1 Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
05/18/2006	WO2006050631A1 Stabilized freeze-dried formulation for cephalosporin derivatives
05/18/2006	WO2006050598A1 Dual antiplatelet/anticoagulant pyridoxine analogs
05/18/2006	WO2006050591A2 Process for the synthesis of poly (vinyl alcohol) and/or poly (vinyl acetate) with spherical morphology and shell- and-nucleus structure and its use in vascular embolization
05/18/2006	WO2006050585A2 Modulation of nitric oxide synthases by betaines
05/18/2006	WO2006050544A2 Tolperison for treating dogs having degenerative spinal symptoms
05/18/2006	WO2006041773A3 Lactam compounds useful as protein kinase inhibitors
05/18/2006	WO2006038006A3 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
05/18/2006	WO2006037480A8 Hexafluoroisopropanol substituted ether derivatives
05/18/2006	WO2006035282A3 Muscarinic receptor antagonists
05/18/2006	WO2006034480A3 Sulfonamide bicyclic compounds
05/18/2006	WO2006034468A8 Methods and compositions for treating hyperglycemic, hyperlipidemic, or hyperinsulinemic disorders
05/18/2006	WO2006034418A3 Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof
05/18/2006	WO2006034341A3 Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
05/18/2006	WO2006033000A3 N-ethyl hydroxyethylamine useful in treating cns conditions
05/18/2006	WO2006030402A3 Dual compartment osmotic delivery device
05/18/2006	WO2006026663A9 Methods for treating congestive heart failure
05/18/2006	WO2006023931A3 Kinase inhibitors
05/18/2006	WO2006021888B1 Dihydrofolate reductase inhibition by epigallocatechin gallate compounds
05/18/2006	WO2006021881A3 Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
05/18/2006	WO2006018625A3 Peripheral benzodiazepine receptor independent superoxide generation
05/18/2006	WO2006018188A3 Substituted hydantoins
05/18/2006	WO2006018184A3 Spirocyclic cyclohexane derivatives
05/18/2006	WO2006016275A3 Gastrin-specific interfering rna
05/18/2006	WO2006015120A3 Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof
05/18/2006	WO2006014429A3 Cidofovir peptide conjugates as prodrugs
05/18/2006	WO2006012504A3 Compounds and methods for treatment of thrombosis
05/18/2006	WO2006008038A8 Methylidene-d-xylopyranosyl-substituted and oxo-d-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and method for the production thereof
05/18/2006	WO2006007227A3 Abnormal cannabidiols for lowering intraocular pressure
05/18/2006	WO2006000867B1 Compositions for topical treatment
05/18/2006	WO2006000224A3 Compositions comprising strontium and vitamin d and uses thereof
05/18/2006	WO2005123053A3 Use of cb2 receptors agonists for the treatment of huntington’s disease
05/18/2006	WO2005121151A3 Thienopyridinone compounds and methods of treatment
05/18/2006	WO2005121074A3 Processes for the preparation of sertraline hydrochloride
05/18/2006	WO2005117895A8 Compositions comprising meloxicam
05/18/2006	WO2005116653A3 Modulators of human g protein-coupled receptors for the treatment of hyperglycemia and related disorders
05/18/2006	WO2005115400A3 Antibiotic compound
05/18/2006	WO2005115346A9 Pharmaceutical composition containing risperidone
05/18/2006	WO2005115333A3 A biomolecule-containing formulation of increased stability
05/18/2006	WO2005112864A3 Method for fostering bone formation and preservation
05/18/2006	WO2005110422A3 Treatment of diseases associated with altered level of amyloid beta peptides
05/18/2006	WO2005107809A8 Antimycobacterial pharmaceutical composition comprising an antitubercular drug
05/18/2006	WO2005107717A3 Oral dosage form for the extended release of biguanide and sulfonylurea
05/18/2006	WO2005107713A3 Swellable dosage form comprising gellan gum
05/18/2006	WO2005105066A3 Histone deacetylases inhibitors against hyperlipidaemias, atherosclerosis, cardiovascular diseases
05/18/2006	WO2005102309A3 In vivo release of endogenous anti-microbial mediators by leukotriene b4 (ltb4) administration
05/18/2006	WO2005102294A3 Transdermal system secured against misuse

1 ... 4252 4253 4254 4255 4256 4257 4258 4259 4260 4261 4262 4263 4264 4265 4266 4267 4268 4269 4270 4271 4272 ... 7860